Trial reportBMC complementary and alternative medicine2018
Dietary geraniol ameliorates intestinal dysbiosis and relieves symptoms in irritable bowel syndrome patients: a pilot study.
Trial report in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions.Frontiers in pharmacology · 2022Pooled it
- Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial.Nutrients · 2022Trial
- The diversity of factors influencing human digestive microbiota in healthy adults and their interaction: a scoping review.BMC nutrition · 2026Article
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
- Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.Journal of clinical medicine · 2025Review
- Very-Low-Absorbable Geraniol for the Treatment of Irritable Bowel Syndrome: A "Real-World" Open-Label Study on 1585 Patients.Nutrients · 2025Article
- The emerging role of honeysuckle flower in inflammatory bowel disease.Frontiers in nutrition · 2025Review
- Plant Monoterpenes and Essential Oils as Potential Anti-Ageing Agents: Insights from Preclinical Data.Biomedicines · 2024Review
- Antifungal Activity of Natural Compounds vs.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC).Molecules (Basel, Switzerland) · 2021Article
- Protective Effect of Geraniol on Oxidative, Inflammatory and Apoptotic Alterations in Isoproterenol-Induced Cardiotoxicity: Role of the Keap1/Nrf2/HO-1 and PI3K/Akt/mTOR Pathways.Antioxidants (Basel, Switzerland) · 2020Article
- Antioxidant, Anti-Inflammatory, and Microbial-Modulating Activities of Essential Oils: Implications in Colonic Pathophysiology.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background(Trans)-3,7-Dimethyl-2,6-octadien-1-ol, commonly called geraniol (Ge-OH), is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties. Ge-OH is a non-toxic compound classified as Generally Recognized As Safe (GRAS) by the US Food and Drug Administration and the European Food Security Agency.
methodsGe-OH was orally administered at a maximum daily dose of 8 mg kg
resultsThe results show that orally administered Ge-OH is a powerful modulator of the intestinal microbial ecosystem, capable of leading to increased relative abundances of Collinsella and especially Faecalibacterium, a well-known health-promoting butyrate producer consistently found to be decreased in IBS patients. Moreover, Ge-OH strongly improved the clinical symptoms of colitis by significantly reducing the score recorded by the VAS-IBS questionnaire. Clinical improvement was associated with a significant reduction in the circulating MIP-1β, a chemokine found to be increased in several IBS patients.
conclusionGe-OH could be a powerful component for food supplement targeted to the treatment of IBS patients.
trial registrationISRCTN47041881 , retrospectively registered on 19th July 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.